Compare STEM & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STEM | ELTX |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.6M | 63.3M |
| IPO Year | 2020 | 2014 |
| Metric | STEM | ELTX |
|---|---|---|
| Price | $4.26 | $1.89 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 4 |
| Target Price | $7.45 | ★ $13.67 |
| AVG Volume (30 Days) | 169.5K | ★ 335.3K |
| Earning Date | 10-28-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.29 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $156,266,000.00 | $2,301,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.49 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 8.08 | N/A |
| 52 Week Low | $3.70 | $1.71 |
| 52 Week High | $32.23 | $16.00 |
| Indicator | STEM | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.24 | 30.64 |
| Support Level | $3.70 | $1.71 |
| Resistance Level | $6.02 | $3.32 |
| Average True Range (ATR) | 0.30 | 0.12 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 49.11 | 53.97 |
Stem Inc is a provider of energy storage systems. The company bundles third-party hardware with its proprietary Athena software to provide customers a turnkey solution. Stem sells its solutions to commercial and industrial customers as well as independent power producers and renewable developers. Its solutions help customers maximize renewable energy generation and help build a cleaner and more resilient grid. The Company operates as one operating segment that is focused exclusively on technology services that transform the way energy is distributed and consumed.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.